Want to join the conversation?
$CAG's FY16 EPS guidance is now based on expectations for comparable results for continuing operations given recent divestiture of private label business, which is classified within discontinued operations. $CAG sees FY16 EPS from continuing operations, adjusting for items impacting comparability, of $2.05-2.07.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.